NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC boosted its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 47.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 423,155 shares of the company’s stock after buying an additional 136,955 shares during the period. NewAmsterdam Pharma makes up approximately 0.9% of Affinity Asset Advisors LLC’s portfolio, making the stock its 29th biggest position. Affinity Asset Advisors LLC owned about 0.47% of NewAmsterdam Pharma worth $8,129,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of NAMS. Sei Investments Co. raised its stake in shares of NewAmsterdam Pharma by 49.1% in the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after acquiring an additional 8,087 shares during the period. Wolverine Asset Management LLC increased its stake in NewAmsterdam Pharma by 117.7% during the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after purchasing an additional 8,394 shares during the period. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma during the second quarter worth about $38,000. Rosalind Advisors Inc. purchased a new position in shares of NewAmsterdam Pharma in the second quarter valued at approximately $194,000. Finally, Opaleye Management Inc. boosted its stake in shares of NewAmsterdam Pharma by 18.8% in the first quarter. Opaleye Management Inc. now owns 315,388 shares of the company’s stock valued at $7,459,000 after purchasing an additional 50,000 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the topic of several recent research reports. Needham & Company LLC initiated coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, August 28th. They set a “buy” rating and a $36.00 target price on the stock. Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $33.80.

NewAmsterdam Pharma Trading Up 0.5 %

Shares of NAMS stock opened at $15.55 on Wednesday. The firm has a fifty day moving average price of $16.77 and a 200 day moving average price of $19.13. NewAmsterdam Pharma has a 12 month low of $5.63 and a 12 month high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.08. The business had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -2.06 earnings per share for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.